Canopy Growth Nears Completion of Strategic Acquisition

Canopy Growth finalizes MTL Cannabis acquisition, aiming for $10M in synergies and a path to profitability by FY2027, following strong shareholder approval.

The Canadian cannabis producer Canopy Growth is on the verge of finalizing a strategically significant acquisition. The integration of MTL Cannabis is slated for completion by March 2026, following near-unanimous shareholder approval of the transaction. This move is anticipated to bolster the company's domestic market position and deliver much-needed margin enhancement.

Strengthening the Financial Foundation

Recent quarterly results underscore the importance of this margin-accretive deal for Canopy Growth. For the third quarter ending December 31, 2025, the company reported net revenue stagnation at $74.5 million. While the broader Canadian recreational and medical cannabis market expanded and its Storz & Bickel subsidiary posted a strong 45% revenue increase, supply chain issues in Europe weighed on performance. The corporation's gross margin contracted to 29%.

Concurrently, there are positive signals on the cost side. The adjusted EBITDA loss narrowed significantly to just $3 million. The company has also stabilized its balance sheet. With cash reserves of $298 million and a debt restructuring completed in January 2026 that extended maturities to 2031, immediate concerns regarding the company's viability have been alleviated for now.

MTL Cannabis Brings Scale and Synergy

Shareholders of MTL Cannabis paved the way for the merger in mid-February with an approval rate of 99.97%. Through this acquisition, Canopy Growth gains a company that generated net revenue of 84 million Canadian dollars and a gross margin of 51% in the twelve months ending September 30, 2025.

Management projects annual cost synergies of approximately $10 million through operational efficiencies, expected to be realized within 18 months of closing. Furthermore, the takeover expands the group's production capacity, a move designed to secure supply for the European medical cannabis market.

Regulatory Landscape and Forward Path

The regulatory environment in the United States remains a pivotal factor for the industry's trajectory. The rescheduling of cannabis to a "Schedule III" substance, initiated by President Donald Trump the previous year, has eased access to banking services and tax deductions for companies. However, stringent competitive conditions and the prohibition on interstate transport continue to hinder rapid expansion in the American market.

The coming weeks will see the final formal closure of the MTL acquisition. If integration proceeds according to plan, CFO Thomas Stewart anticipates the combined entity will achieve a gross margin in the mid-to-high 30 percent range in the near term. This structural transformation is the fundamental prerequisite for management's stated goal: reaching a positive adjusted EBITDA in the 2027 fiscal year.